Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study..

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
2.

Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients.

Duffau P, Wittkop L, Lazaro E, le Marec F, Cognet C, Blanco P, Moreau JF, Dauchy FA, Cazanave C, Vandenhende MA, Bonnet F, Thiebaut R, Pellegrin I; ANRS CO3 Aquitaine Cohort Study Group..

AIDS. 2015 Oct 23;29(16):2099-108. doi: 10.1097/QAD.0000000000000807.

PMID:
26544576
3.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group..

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

PMID:
26216031
4.

In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.

Sibiude J, Le Chenadec J, Bonnet D, Tubiana R, Faye A, Dollfus C, Mandelbrot L, Delmas S, Lelong N, Khoshnood B, Warszawski J, Blanche S; French National Agency for Research on AIDS and Viral Hepatitis French Perinatal Cohort/Protease Inhibitor Monotherapy Evaluation Trial..

Clin Infect Dis. 2015 Jul 15;61(2):270-80. doi: 10.1093/cid/civ260. Epub 2015 Apr 1.

PMID:
25838291
5.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group.; Royal Free Hospital Clinic Cohort.; INSIGHT study group.; SMART study group.; ESPRIT study group..

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar 31.

6.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group..

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
7.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

8.

Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort.

Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, Neau D, Cazanave C, Pellegrin JL, Dabis F, Morlat P, Chêne G; GECSA study group..

PLoS One. 2014 Jul 30;9(7):e102671. doi: 10.1371/journal.pone.0102671. eCollection 2014 Jul 30.

9.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group..

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
10.

AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies.

Luz PM, Bruyand M, Ribeiro S, Bonnet F, Moreira RI, Hessamfar M, Campos DP, Greib C, Cazanave C, Veloso VG, Dabis F, Grinsztejn B, Chêne G; IPEC/FIOCRUZ Cohort and the Aquitaine ANRS C03 Study Group..

BMC Infect Dis. 2014 May 21;14:278. doi: 10.1186/1471-2334-14-278.

11.

Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.

Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group..

HIV Med. 2014 Nov;15(10):595-603. doi: 10.1111/hiv.12162. Epub 2014 May 19.

12.

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.

Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group..

BMC Nephrol. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51.

13.

Decline in locomotor functions over time in HIV-infected patients.

Richert L, Brault M, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G, Dehail P; Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA)..

AIDS. 2014 Jun 19;28(10):1441-9. doi: 10.1097/QAD.0000000000000246.

PMID:
24566096
14.

Handgrip strength is only weakly correlated with physical function in well-controlled HIV infection: ANRS CO3 Aquitaine Cohort.

Richert L, Brault M, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G, Dehail P; Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA)..

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e25-7. doi: 10.1097/QAI.0b013e3182a03db8. No abstract available.

PMID:
24419068
15.

Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group..

BMC Infect Dis. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471.

16.

Associations between immune depression and cardiovascular events in HIV infection.

Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group..

AIDS. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3.

PMID:
23842128
17.

Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.

Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, Gerard Y, Lazaro E, Duffau P, Neau D, Bonnet F, Chêne G; Groupe D’epidémiologie Clinique du Sida en Aquitaine (Gecsa)..

PLoS One. 2013 Jun 12;8(6):e66223. doi: 10.1371/journal.pone.0066223. Print 2013.

18.

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group..

J Infect Dis. 2013 May 1;207(9):1359-69. doi: 10.1093/infdis/jit043. Epub 2013 Feb 4.

19.

Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort.

Lawson-Ayayi S, Cazanave C, Kpozehouen A, Barthe N, Mehsen N, Hessamfar M, Dupon M, Dabis F, Neau D; Groupe Epidémiologie Clinique du SIDA en Aquitaine (GECSA)..

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):430-5. doi: 10.1097/QAI.0b013e3182845d88.

PMID:
23296138
20.

Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort.

Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Dupon M, Hessamfar M, Ventura M, Malvy D, Dabis F, Pellegrin JL, Moreau JF, Thiébaut R, Pellegrin I; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine..

J Infect Dis. 2013 Feb 15;207(4):622-7. doi: 10.1093/infdis/jis732. Epub 2012 Nov 29.

PMID:
23204178

Supplemental Content

Loading ...
Support Center